Non-alcoholic fatty liver disease (NAFLD)

NAFLD is a silent epidemic that is highly correlated to the rise in obesity and type-2 diabetes throughout developed and developing nations. This widespread metabolic disease is estimated to affect 25% of the world population, with nearly 100 million Americans living with some form of the disease, with 15-25 million of such patients estimated to have progressed to the most severe form of the disease, non-alcoholic steatohepatitis (NASH). 

The HepGene™ liquid biopsy program, designed for early detection, confirmatory diagnosis and progression/reversal monitoring, is positioned to provide an objective diagnosis that can be used to motivate patients to make radical changes in their lifestyle and diet in the earliest stages, and to inform physicians in accelerating patients towards the most effective intervention and treatment pathway. 

The patent-pending HepGene™ NAFLD program has been extensively validated, with our team of internal and external partners successfully completing 49 R&D studies, including 28 independent cross-cohort validations, across 6 independent patient cohorts and 498 case-control clinical specimens, with strong reproducibility and best-in-class diagnostic sensitivity and specificity achieved in all studies.